Medicare ESA Policy May Find Support In FDA Letter But J&J Sees Differently

Key Democratic legislators are spotlighting an FDA letter on erythropoiesis-stimulating agents as indicating agreement between FDA and Medicare policies, but some stakeholders interpret it as pointing out differences between the agencies